CONNECT WITH US
HealthTech

HealthTech

Astellas buys option to preclinical IL-12 cancer drug from Audax Biosciences

Endpoints News logo

Published on

Add as a preferred source on Google
Astellas buys option to preclinical IL-12 cancer drug from Audax Biosciences

Astel­las has tak­en an ex­clu­sive op­tion to li­cense a pre­clin­i­cal im­muno-on­col­o­gy as­set from Aus­tralian biotech Au­dax Bio­sciences.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Fer­ring to ac­quire ovary-in-a-dish start­up Ga­me­to for up to $1.38B October 27, 2026

Lil­ly’s mu­sic-lov­ing, in­tense lead deal­mak­er knows what he wants October 26, 2026

Corx­el to take oral GLP-1 pub­lic in the US via SPAC October 26, 2026

Backed by Amish and Men­non­ites, a new kind of gene ther­a­py com­pa­ny takes shape

Trea­sury's COINS rule draft would nar­row the path for Chi­na biotech deal­mak­ing, ex­perts say

An­throp­ic's lat­est biotech buy is a one-man stealth start­up run by a pseu­do­ny­mous Twit­ter poster



Source link
Related Topics:HealthTech

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.